Eloxx Adds Kalydeco to Ongoing Phase 2 Program Testing ELX-02

Eloxx Adds Kalydeco to Ongoing Phase 2 Program Testing ELX-02

293485

Eloxx Adds Kalydeco to Ongoing Phase 2 Program Testing ELX-02

Eloxx Pharmaceuticals has announced that it’s now added the approved cystic fibrosis (CF) therapy Kalydeco (ivacaftor) to its global Phase 2 clinical program for ELX-02. Ongoing ELX-02 Phase 2 clinical trials, launched in 2019 with four treatment arms, are evaluating the safety and possible dosing of the investigational therapy for CF. Now, a fifth treatment arm has been added to evaluate the safety of Kalydeco in combination with ELX-02 in CF patients with at least one G542X…

You must be logged in to read/download the full post.